Iron Path Capital

We are pleased to announce the final closing of Iron Path Capital Fund I (“Fund I”), exceeding the $250 million target with total commitments of $273 million. “We are extremely grateful for the investors that have decided to partner with us in our inaugural institutional fund,” said Rob Reistetter, Managing Partner and co-founder of Iron Path. “This marks an important achievement for the firm and is a reflection of our differentiated capabilities and the strong team that we have built over our first three years.” Iron Path Capital targets control investments in lower-middle market specialty industrial and healthcare companies, in partnership with founders and managers, to build and grow great businesses. We focus on sectors where we have deep expertise and where we can create transformational outcomes with the operational resources of the Full Immersion Operations team (“FIOps™”). “Our approach includes developing an investment thesis and partnering with founders and managers to scale businesses organically and with strategic acquisitions,” said Scott Mraz, fellow co-founder and Managing Partner of Iron Path. “We have curated a team of limited partners, strategic advisors and Iron Path professionals who share our unique vision and our steadfast values.” M2O Private Fund Advisors acted as the exclusive placement agent. Foley & Lardner LLP served as fund counsel.

Shout out to our portfolio company PureTech Scientific for successfully hitting its first big transformation milestone: a move to the cloud with a unified ERP technology platform that fully transitions employees, customers and vendors with minimal disruption. Kudos to the team and partner SAP for an impressive (and successful) 14-week implementation!

Iron Path Capital today announced a new strategic partnership with TruTech Servo Motors & Systems, marking our first investment into a broader roll-up strategy in industrial automation and motion control. TruTech is a technology leader in the design, engineering, and manufacturing of custom electronic motors for use in high-performance applications, and we’re excited to welcome Founder and CEO Ted Paskvan to our team of Mountain Climbers! Get the full story: https://lnkd.in/g9Vryn-s #PrivateEquity #motioncontrolcomponents #componentmanufacturing #automation

We are thrilled to announce that PureTech Scientific, founded and backed by Iron Path Capital, has successfully completed its acquisition of the Glycolic Acid business from The Chemours Company (NYSE: CC) for $137 million in cash. This acquisition positions PureTech Scientific as the global leader in organic synthesis of ultra-high purity alpha hydroxy acids, serving the Life Sciences and Specialty Chemical industries. Now that’s something to celebrate! 🥂 Get the full story here: https://lnkd.in/g2p4bn4B #lifesciences #specialtychemicals #privateequity Scott Mraz Rob Reistetter James Kanicky Jeffrey Horsager, MBA

Say hello to VION Biosciences. We’re excited to announce a partnership with Aldon Corporation, a top private-label manufacturer and distributor for healthcare, life sciences, and STEM industries. This marks the second investment in a go-forward roll-up platform in the life sciences sector for Iron Path Capital. VION Biosciences will be led by life sciences industry vet Mark Thornton. Read the full release and learn more about VION Biosciences 👉 https://lnkd.in/gskstFe5 #lifesciences #specialtychemicals #privateequity Scott Mraz Rob Reistetter